Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1h-purine-2,6-dione
2. Kw 6002
3. Kw-6002
4. Kw6002
1. 155270-99-8
2. Kw-6002
3. Kw 6002
4. Istradefylline (kw-6002)
5. Nouriast
6. Nourianz
7. 8-[(e)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-purine-2,6 -dione
8. (e)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-1h-purine-2,6(3h,7h)-dione
9. 8-[(e)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
10. (e)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
11. 2gz0lik7t4
12. Chembl431770
13. (e)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dione
14. 8-((1e)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dione
15. 8-[(e)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1h-purine-2,6-dione
16. Kw6002
17. Unii-2gz0lik7t4
18. Istradefyline
19. Istradefylline (jan/usan/inn)
20. Istradefylline [usan:inn:jan]
21. Ncgc00253737-01
22. Nourianz (tn)
23. Nouriast (tn)
24. Istradefylline [usan]
25. Istradefylline [mi]
26. Dsstox_cid_31441
27. Dsstox_rid_97327
28. Istradefylline [inn]
29. Istradefylline [jan]
30. Dsstox_gsid_57652
31. Mls006010633
32. Schembl633262
33. Schembl633263
34. Gtpl5608
35. Istradefylline [who-dd]
36. Dtxsid7057652
37. Chebi:134726
38. Hms3884p16
39. Istradefylline, >=98% (hplc)
40. Bcp02194
41. Zinc3803921
42. Istradefylline [orange Book]
43. Tox21_113855
44. Bdbm50176050
45. Mfcd00928421
46. S2790
47. Akos015966268
48. Am84508
49. Bcp9000824
50. Ccg-268457
51. Cs-0737
52. Db11757
53. 1h-purine-2,6-dione, 3,7-dihydro-1,3-diethyl-8-(2-(3,4-dimethoxyphenyl)ethenyl)-7-methyl-, (e)-
54. Ac-30957
55. Hy-10888
56. Ls-14789
57. Smr004701638
58. Cas-155270-99-8
59. I1100
60. Sw220139-1
61. D04641
62. Kw 6002;kw-6002;kw6002
63. 270i998
64. L001483
65. Q905783
66. Sr-01000945278
67. J-009183
68. J-519355
69. Sr-01000945278-1
70. Brd-k40096621-001-01-2
71. 1,3-diethyl-7-methyl-8-(3,4-dimethoxystyryl)xanthine
72. (e)- 8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
73. 8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-1h-purine-2,6(3h,7h)-dione
74. 8-[2-(3,4-dimethoxy-phenyl)-vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-purine-2,6-dione
75. 8-[2-(3,4-dimethoxy-phenyl)-vinyl]-1,3-diethyl-7-methyl-3,9-dihydro-purine-2,6-dione
76. (e)-8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1h-purine-2,6-dione
77. 8-[(1e)-2-(2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1h-purine-2,6-dione
78. 8-[(e)-2-(3,4-dimethoxy-phenyl)-vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-purine-2,6-dione
Molecular Weight | 384.4 g/mol |
---|---|
Molecular Formula | C20H24N4O4 |
XLogP3 | 2.5 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 384.17975526 g/mol |
Monoisotopic Mass | 384.17975526 g/mol |
Topological Polar Surface Area | 76.9 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 613 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Istradefylline is indicated in adjunct to levodopa and carbidopa in the treatment of Parkinson's disease.
Treatment of Parkinson's disease
Istradefylline is indicated in adults as an adjunctive treatment to levodopa based regimens in patients with Parkinson's disease (PD) experiencing OFF time.
Istradefylline is a selective adenosine A2A receptor inhibitor. It has a long duration of action as it is given once daily and has a half life of 64-69 hours. Patients taking this medication should be monitored for dyskinesia, hallucinations, and lack of impulse control. Consider dose reductions for these patients.
Adenosine A2 Receptor Antagonists
Compounds that selectively bind to and block the activation of ADENOSINE A2 RECEPTORS. (See all compounds classified as Adenosine A2 Receptor Antagonists.)
N04
N - Nervous system
N04 - Anti-parkinson drugs
N04C - Other antiparkinson drugs
N04CX - Other antiparkinson drugs
N04CX01 - Istradefylline
Absorption
Istradefylline reaches a Cmax of 181.1ng/mL with a Tmax of 2.0h and an AUC of 11,100ng\*h/mL. M1, the primary active metabolite, reaches a Cmax of 4.34ng/mL with a Tmax of 3.5h. The M8 metabolite reaches a Cmax of 12.6ng/mL with a Tmax of 3.0h and an AUC of 610ng\*h/mL.
Route of Elimination
A 3mg/kg oral dose given to male rats was 17.6% elminated in the urine and 68.3% eliminated in the feces. In urine, 5.31% of the total dose was the M3 metabolite and 1.96% of the total dose was the M1 metabolite. In feces, 30.60% of the total dose was the M3 metabolite, 9.34% of the total dose was the M1 metabolite, 8.33% of the total dose was the M10 metabolite, and 1.62% of the total dose was unchanged istradefylline.
Volume of Distribution
The apparent volume of distribution of istradefylline is 448-557L.
Clearance
The apparent clearance of istradefylline is 4.1-6.0L/h.
The primary metabolite found in urine is the active 4'-O-monodesmethyl istradefylline (M1). Istradefylline is metabolized mainly by CYP1A1, CYP3A4, and CYP3A5. CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C18, and CYP2D6 also partly contribute the the metabolism of istradefylline. Other identified metabolites are 1--hydroxylated-4-O-demethyl istradefylline (M2), 3,4-O-didemethyl istradefylline (M3), M1 sulfate conjugate (M4), M1 glucuronide (M5), 1--hydroxylated istradefylline (M8) and hydrogenated M3 (M10).
The terminal elimination half life of istradefylline was 64-69 hours.
Istradefylline is a selective adenosine A2A receptor inhibitor. These receptors are found in the basal ganglia, a region of the brain that suffers degeneration in Parkinson's disease, and is also significantly involved in motor control. A2A receptors are also expressed on GABAergic medium spiny neurons within the indirect striato-pallidal pathway. The GABAergic action of this pathway is thereby reduced. Istradefylline has 56 times the affinity for A2A receptors than A1 receptors.
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Istradefylline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Istradefylline, including repackagers and relabelers. The FDA regulates Istradefylline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Istradefylline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Istradefylline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Istradefylline supplier is an individual or a company that provides Istradefylline active pharmaceutical ingredient (API) or Istradefylline finished formulations upon request. The Istradefylline suppliers may include Istradefylline API manufacturers, exporters, distributors and traders.
click here to find a list of Istradefylline suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Istradefylline DMF (Drug Master File) is a document detailing the whole manufacturing process of Istradefylline active pharmaceutical ingredient (API) in detail. Different forms of Istradefylline DMFs exist exist since differing nations have different regulations, such as Istradefylline USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Istradefylline DMF submitted to regulatory agencies in the US is known as a USDMF. Istradefylline USDMF includes data on Istradefylline's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Istradefylline USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Istradefylline suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Istradefylline Drug Master File in Japan (Istradefylline JDMF) empowers Istradefylline API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Istradefylline JDMF during the approval evaluation for pharmaceutical products. At the time of Istradefylline JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Istradefylline suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Istradefylline as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Istradefylline API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Istradefylline as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Istradefylline and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Istradefylline NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Istradefylline suppliers with NDC on PharmaCompass.
Istradefylline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Istradefylline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Istradefylline GMP manufacturer or Istradefylline GMP API supplier for your needs.
A Istradefylline CoA (Certificate of Analysis) is a formal document that attests to Istradefylline's compliance with Istradefylline specifications and serves as a tool for batch-level quality control.
Istradefylline CoA mostly includes findings from lab analyses of a specific batch. For each Istradefylline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Istradefylline may be tested according to a variety of international standards, such as European Pharmacopoeia (Istradefylline EP), Istradefylline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Istradefylline USP).
LOOKING FOR A SUPPLIER?